SSY Group Ltd LJUIF
Morningstar’s Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile
SSY Group Ltd is a specialty and generic drug manufacturing company. The company reports multiple segments including pharmaceutical products, medical materials, services income, raw materials, and by-products and rental income. The company derives a vast majority of its revenue principally from the sale of finished medicines to hospitals and distributors. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials. Over 95% of SSY Group's revenue and operating profits are derived from China.
Hong Kong, Hong Kong